BioCentury | Feb 15, 2019
Clinical News

Complete response letter for Motif's antibiotic

...FDA issued a complete response letter to an NDA for iclaprim (MTF-100) from Motif Bio plc (LSE:MTFB; NASDAQ:MTFB...
...FDA. Motif Bio plc (LSE:MTFB; NASDAQ:MTFB), London, U.K. Product: Iclaprim (MTF-100) Business: Infectious Sandi Wong iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Jan 17, 2019
Regulation

Products on shutdown standby

...lines 2/2/19 Standard Sanofi (Euronext:SAN; NASDAQ:SNY) Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (TTP) 2/6/19 Priority Motif Bio plc...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Inc. (NYSE:MRK) Keytruda pembrolizumab First-line monotherapy for non-small cell lung cancer (NSCLC) PDUFA date 4/11/19 Motif Bio plc...
BioCentury | Aug 17, 2018
Clinical News

Motif's antibiotic gets Priority Review

...Motif gained £1.40 to £34.20 in London and added $1.10 (14%) to $9 on NASDAQ. Motif Bio plc...
...LSE:MTFB; NASDAQ:MTFB), London, U.K. Product: Iclaprim (MTF-100) (formerly Mersarex) Business: Infectious Sandi Wong iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Aug 14, 2018
Company News

Motif's antibiotic gets Priority Review

...£34.20 in London and added $1.10 (14%) to $9 on NASDAQ. Sandi Wong iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) Remestemcel-L Acute GvHD in children Ph III MSC-100-IV data 2Q18 Motif Bio plc...
BioCentury | Mar 23, 2018
Clinical News

Motif delays NDA for iclaprim in ABSSSIs

...DHFR). Motif Bio plc (LSE:MTFB; NASDAQ:MTFB), London, U.K. Product: Iclaprim (MTF-100) Business: Infectious Jennie Walters iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Mar 20, 2018
Company News

Motif delays NDA for iclaprim in ABSSSIs

...£33 in London and was off $0.80 to $9.40 on NASDAQ. Jennie Walters iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

.../ Allergan plc (NYSE:AGN) Abicipar pegol Wet age-related macular degeneration (AMD) Ph III data 2H18 Motif Bio plc...
BioCentury | Oct 6, 2017
Clinical News

Motif's iclaprim meets in second Phase III for ABSSSIs

...in 2015 through a merger with Nuprim Inc., which was launched by former Arpida executives. Motif Bio plc...
...point and no requirement for additional antibiotics Status: Phase III data Milestone: Submit NDA (1Q18) Alicia Parker iclaprim MTF-100 Motif Bio plc Dihydrofolate...
Items per page:
1 - 10 of 32
BioCentury | Feb 15, 2019
Clinical News

Complete response letter for Motif's antibiotic

...FDA issued a complete response letter to an NDA for iclaprim (MTF-100) from Motif Bio plc (LSE:MTFB; NASDAQ:MTFB...
...FDA. Motif Bio plc (LSE:MTFB; NASDAQ:MTFB), London, U.K. Product: Iclaprim (MTF-100) Business: Infectious Sandi Wong iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Jan 17, 2019
Regulation

Products on shutdown standby

...lines 2/2/19 Standard Sanofi (Euronext:SAN; NASDAQ:SNY) Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (TTP) 2/6/19 Priority Motif Bio plc...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...Inc. (NYSE:MRK) Keytruda pembrolizumab First-line monotherapy for non-small cell lung cancer (NSCLC) PDUFA date 4/11/19 Motif Bio plc...
BioCentury | Aug 17, 2018
Clinical News

Motif's antibiotic gets Priority Review

...Motif gained £1.40 to £34.20 in London and added $1.10 (14%) to $9 on NASDAQ. Motif Bio plc...
...LSE:MTFB; NASDAQ:MTFB), London, U.K. Product: Iclaprim (MTF-100) (formerly Mersarex) Business: Infectious Sandi Wong iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Aug 14, 2018
Company News

Motif's antibiotic gets Priority Review

...£34.20 in London and added $1.10 (14%) to $9 on NASDAQ. Sandi Wong iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Apr 6, 2018
Finance

Smid-cap smorgasbord

...JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) Remestemcel-L Acute GvHD in children Ph III MSC-100-IV data 2Q18 Motif Bio plc...
BioCentury | Mar 23, 2018
Clinical News

Motif delays NDA for iclaprim in ABSSSIs

...DHFR). Motif Bio plc (LSE:MTFB; NASDAQ:MTFB), London, U.K. Product: Iclaprim (MTF-100) Business: Infectious Jennie Walters iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Mar 20, 2018
Company News

Motif delays NDA for iclaprim in ABSSSIs

...£33 in London and was off $0.80 to $9.40 on NASDAQ. Jennie Walters iclaprim (MTF-100, mersarex, AR-100, Ro-48-2622) Motif Bio plc Dihydrofolate...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

.../ Allergan plc (NYSE:AGN) Abicipar pegol Wet age-related macular degeneration (AMD) Ph III data 2H18 Motif Bio plc...
BioCentury | Oct 6, 2017
Clinical News

Motif's iclaprim meets in second Phase III for ABSSSIs

...in 2015 through a merger with Nuprim Inc., which was launched by former Arpida executives. Motif Bio plc...
...point and no requirement for additional antibiotics Status: Phase III data Milestone: Submit NDA (1Q18) Alicia Parker iclaprim MTF-100 Motif Bio plc Dihydrofolate...
Items per page:
1 - 10 of 32